Literature DB >> 25717061

Identification of Early-Onset Preeclampsia-Related Genes and MicroRNAs by Bioinformatics Approaches.

Jing Song1, Yue Li2, Rui Fang An3.   

Abstract

BACKGROUND: Early-onset preeclampsia (EOPET), resulting in intrauterine growth restriction, has serious impact on maternal, perinatal, and neonatal livability worldwide. The current study conducted bioinformatics analyses to screen key genes and microRNAs (miRNAs) involved in EOPET and thus to explore the molecular mechanisms of EOPET.
METHODS: The microarray data set GSE44711 containing 8 EOPET placentas and 8 gestational age-matched controls was obtained from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened and subjected to gene ontology functional enrichment analysis. Then, Human Protein Reference Database was used to construct protein-protein interaction (PPI) network of DEGs. Besides, we predicted EOPET-associated miRNAs and built the miRNA regulatory network.
RESULTS: A total of 150 DEGs including 26 upregulated and 124 downregulated genes were obtained. Corticotropin releasing hormone (CRH) and vitronectin (VTN) was the most significantly upregulated and downregulated genes, respectively. The DEGs were mainly related to the biological process (BP) of pregnancy, hormone-involved process, and formation of extracellular region. Analysis of PPI network revealed that fibronectin 1(FN1), FBJ murine osteosarcoma viral oncogene homolog (FOS), CD247 molecule (CD247), VTN, and interleukin 2 receptor, beta (IL2RB) were the top 5 DEGs with highest node degree. Furthermore, many EOPET-associated miRNAs were identified and miR-142-3p was the most significant one. Additionally, multiple miRNAs, such as miR-200b/c and miR-27a/b, were predicted to regulate the expression of several key DEGs.
CONCLUSION: The current study identified several regulators in EOPET, which may contribute to interpret the molecular mechanism of EOPET and develop novel biomarkers and therapeutic targets for EOPET.
© The Author(s) 2015.

Entities:  

Keywords:  bioinformatics; differentially expressed genes; early-onset preeclampsia; miRNA

Mesh:

Substances:

Year:  2015        PMID: 25717061     DOI: 10.1177/1933719115570898

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  6 in total

Review 1.  Candidate Gene, Genome-Wide Association and Bioinformatic Studies in Pre-eclampsia: a Review.

Authors:  Semone Thakoordeen; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2018-08-29       Impact factor: 5.369

2.  Expression of miRNA-1233 in placenta from patients with hypertensive disorder complicating pregnancy and its role in disease pathogenesis.

Authors:  Wenyu Zhong; Hui Peng; Ailing Tian; Yongqing Wei; Hua Li; Jingxia Tian; Xingbo Zhao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Consensus strategy in genes prioritization and combined bioinformatics analysis for preeclampsia pathogenesis.

Authors:  Eduardo Tejera; Maykel Cruz-Monteagudo; Germán Burgos; María-Eugenia Sánchez; Aminael Sánchez-Rodríguez; Yunierkis Pérez-Castillo; Fernanda Borges; Maria Natália Dias Soeiro Cordeiro; César Paz-Y-Miño; Irene Rebelo
Journal:  BMC Med Genomics       Date:  2017-08-08       Impact factor: 3.063

4.  Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis.

Authors:  Shouling Luo; Nannan Cao; Yao Tang; Weirong Gu
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

5.  An integrative bioinformatics analysis of microarray data for identifying hub genes as diagnostic biomarkers of preeclampsia.

Authors:  Keling Liu; Qingmei Fu; Yao Liu; Chenhong Wang
Journal:  Biosci Rep       Date:  2019-09-03       Impact factor: 3.840

6.  Integrated microarray analysis of key genes and a miRNA‑mRNA regulatory network of early‑onset preeclampsia.

Authors:  Hao Zhang; Lu Xue; Yan Lv; Xiang Yu; Yiwei Zheng; Zhijing Miao; Hongjuan Ding
Journal:  Mol Med Rep       Date:  2020-09-30       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.